![](https://investorshub.advfn.com/uicon/358623.png?cb=1554503635)
Monday, March 27, 2017 10:16:29 PM
Start watching for the undisclosed drug filings.
$$$$$$$$$$$$
Elite working on 7 AD opiods concurrently
$Generic Products$$
Commercial Product
Branded Product Equivalent
Therapeutic Category
1. Hydromorphone Hydrochloride
8 mg Tablets
Dilaudid®
Pain
2. Naltrexone Hydrochloride
50 mg Tablets
Revia®
Opioid Antagonist
3. Phentermine HCl
37.5 mg Tablets
Adipex-P®
Bariatric
4. Phentermine HCI
15 mg and 30 mg Capsules
Adipex-P®
Bariatric
5. Phendimetrazine Tartrate
35 mg Tablets, USP
Bontril®
Bariatric
6. Isradipine
2.5 mg and 5 mg Capsules
N/A
Cardiovascular
7. Hydroxyzine HCI
10 mg, 25 mg, 50 mg Tablets
Atarax®, Vistaril®
Antihistamine
8. Dantrolene Sodium
25 mg, 50 mg and 100 mg Capsules *
Dantrium®
Skeletal Muscle Relaxant
9. Loxapine
5 mg, 10 mg, 25 mg, 50 mg Capsules *
N/A
Antipsychotic
10. Additional Approved ANDA's *
Undisclosed
Undisclosed
* pending manufacturing site transfer
$BRANDED PRODUCTS$$
Commercial Product
Therapeutic Category
Partner
11. Lodrane D®
OTC Allergy
Valeant Pharmaceuticals International, Inc.
$CONTRACT MANUFACTURING$$
Commercial Product
Branded Product Equivalent
Therapeutic Category
Partner
12. Methadone Hydrochloride
10 mg Tablets
Dolophine®
Pain
Ascend Laboratories, LLC
$GENERIC PIPELINE$$
Programs Under Development
Branded Product Equivalent
Therapeutic Category
Development Stage
13. ELI-300 Opioid
Undisclosed
Pain
Early Development
14. ELI-301 Opioid
Undisclosed
Pain
Early Development
15. Oxycodone HCl and Acetaminophen, USP 325 mg
5 mg, 7.5 mg, 10 mg Tablets
Percocet
Pain
Pending FDA Approval
16. Hydrocodone bitartrate and Acetaminophine tablets, 2.5mg/325mg, 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets
Norco
Pain
Pending FDA Approval
17. Undisclosed Generic
Undisclosed
Undisclosed
Pending FDA Approval
18. Elite/SunGen Generic #1
Undisclosed
CNS Stimulant
In Development
19. Elite/SunGen Generic #2
Undisclosed
CNS Stimulant
In Development
20. Elite/SunGen Generic #3
Undisclosed
Beta-Blocker
In Development
21. Elite/SunGen Generic #4
Undisclosed
Beta-Blocker
In Development
22. Generic Troxyca
Pain
23. Generic Embeda
Pain
24. Generic OxyContin
$BRANDED PIPELINE$$
Development Stage
Partner
25. SequestOx™ (ELI-200) Opioid
Pain
NDA Submitted
PDUFA date: July 14, 2016
Epic Pharma LLC
26. ELI-201 ER Opioid
Troxyca equivalent
Pain
Pivotal Bio-equivalence
27. ELI-202 Opioid
Pain
Pivotal Bio-equivalence
28. ELI-216 Opioid ER 24hr (once/day)
Pain
Process Development
29. ELI-400 Opioid
Pain
Process Development
30. ELI-500 Opioid
Pain
Process Development
31. ELI-501 Opioid
Pain
Early Development
32. ELI-600 Opioid
Pain
Process development
You Can Tell A Man's Character By The Way He Treats Those Who Can Do Nothing For Him
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 09:30:05 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/31/2023 08:20:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2023 08:15:16 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM